Literature DB >> 29450347

Combined etiology for bilateral and simultaneous optic neuropathy in a patient with ciancobalamin deficit and hepatitis C treated with peg-interferon and ribavirin.

Anca Delia Pantalon1, Ciprian Danielescu1, Dorin Chiseliță1.   

Abstract

We report the case of a 53-year-old female patient who developed bilateral sudden visual acuity loss after 15 weeks from the initiation of Peg-Interferon and Ribavirin treatment for hepatitis C. Debut was simultaneous and asymmetric, reported in the morning, at awakening. No pain or other symptom was reported by the patient. Results. At presentation, visual acuity was 0.2 in RE and 3/ 50 in LE. Pupillary reflexes were sluggish and severe dyschromatopsia was documented in both eyes (Ishihara plates). Fundus examination revealed bilateral pale optic disc edema, more prominent in LE, with splinter hemorrhages in the RNFL around the optic disk. Visual field exam demonstrated severe defects in 3 quadrants of the RE, whereas in the LE, it was impossible to perform the investigation due to VA<0.1. Neurologic evaluation was normal; other possible causes of systemic vasculitis were excluded by negative lab tests. Acute inflammatory markers (fibrinogen and ESR) and mild pancytopenia were the only documented laboratory changes in this patient. Anamnesis cleared the traditional risk factors for conventional AION (hypertension, diabetes, ischemic heart disease, and hypercholesterolemia). Cranial and orbital CT scan and MRI findings were normal. Patient was withdrawn from the Interferon and Ribavirin treatment and was administered methyl prednisolone pulse therapy (1g/ day) for 3 days, continued with oral Prednisone (60 mg/ day) tapered slowly for over 12 weeks. VA increased to 0.8 during treatment in the RE, but visual recovery in the LE was not as spectacular (0.16) as in the fellow eye. Modified latencies and amplitudes in evoked visual potentials examination during 4 months time emphasized bilateral optic atrophy. Optic nerve sufferance was amplified by a low level of vitamin B12, detected by chance at the last eye visit. Due to the general condition, dietary supplementation was not possible. Conclusion. A case of a patient with bilateral and simultaneous NAION caused by IFN and Ribavirin treatment for hepatitis C, who was also vitamin B12 deficient, was analyzed. Therefore, a combined etiology for optic atrophy was explained.

Entities:  

Keywords:  Peg-Interferon; bilateral simultaneous AION; hepatitis C; vitamin B12 deficit

Mesh:

Substances:

Year:  2016        PMID: 29450347      PMCID: PMC5719336     

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  14 in total

Review 1.  Literature systematic review on the ophthalmological side effects of interferons.

Authors:  Yara Dadalti Fragoso; Marina Sanchez Sahm Paggiaro; Roberta Mastromauro; Gabriela da Silva Jacondino; Heather Marion Wilson
Journal:  Arq Bras Oftalmol       Date:  2011 Jul-Aug       Impact factor: 0.872

Review 2.  The interferons. Mechanisms of action and clinical applications.

Authors:  S Baron; S K Tyring; W R Fleischmann; D H Coppenhaver; D W Niesel; G R Klimpel; G J Stanton; T K Hughes
Journal:  JAMA       Date:  1991-09-11       Impact factor: 56.272

3.  Anterior ischemic optic neuropathy in a patient with hepatitis C treated with interferon-alpha and ribavirin.

Authors:  Boris Knyazer; Tova Lifshitz; Mira Marcus; Asaff Kratz; Alex Zlotnik; Jaime Levy
Journal:  Isr Med Assoc J       Date:  2011-04       Impact factor: 0.892

4.  Intraocular hemorrhage developing during interferon therapy.

Authors:  K Kuga; S Hasumura; S Nagamori; G Toda; K Kitahara
Journal:  Intern Med       Date:  1996-01       Impact factor: 1.271

5.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

Authors:  P Bailon; A Palleroni; C A Schaffer; C L Spence; W J Fung; J E Porter; G K Ehrlich; W Pan; Z X Xu; M W Modi; A Farid; W Berthold; M Graves
Journal:  Bioconjug Chem       Date:  2001 Mar-Apr       Impact factor: 4.774

6.  Side effects of high-dose interferon therapy for chronic hepatitis C.

Authors:  T Okanoue; S Sakamoto; Y Itoh; M Minami; K Yasui; M Sakamoto; K Nishioji; T Katagishi; Y Nakagawa; H Tada; Y Sawa; M Mizuno; K Kagawa; K Kashima
Journal:  J Hepatol       Date:  1996-09       Impact factor: 25.083

7.  Acute onset of ocular complications with interferon.

Authors:  H Yamada; K Mizobuchi; Y Isogai
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

8.  Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis type C.

Authors:  M Ayaki
Journal:  Br J Ophthalmol       Date:  1994-03       Impact factor: 4.638

9.  Interferon-associated retinopathy.

Authors:  D R Guyer; J Tiedeman; L A Yannuzzi; J S Slakter; D Parke; J Kelley; R A Tang; M Marmor; G Abrams; J W Miller
Journal:  Arch Ophthalmol       Date:  1993-03

10.  Bilateral retrobulbar optic neuropathy in the setting of interferon alpha-2a therapy.

Authors:  Dujon R W Fuzzard; Heather G Mack; R C Andrew Symons
Journal:  Case Rep Ophthalmol       Date:  2014-08-27
View more
  2 in total

Review 1.  Optic neuropathy as a presenting feature of vitamin B-12 deficiency: A systematic review of literature and a case report.

Authors:  Fateen Ata; Ammara Bint I Bilal; Saad Javed; Hammad Shabir Chaudhry; Rohit Sharma; Rubab Fatima Malik; Hassan Choudry; Anand Bhaskaran Kartha
Journal:  Ann Med Surg (Lond)       Date:  2020-11-05

2.  Quantification of peripapillary vessel density in non-arteritic anterior ischemic optic neuropathy patients with optical coherence tomography angiography.

Authors:  Yufang Su; Song Zhang; Guisen Zhang; Yingru Liu; Zhiguo Du; Daming Li; Lei Liu
Journal:  Quant Imaging Med Surg       Date:  2022-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.